Development and Use of the Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Axicabtagene Ciloleucel in Large B-Cell Lymphoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Development and Use of the Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Axicabtagene Ciloleucel in Large B-Cell Lymphoma

Published:2020-02-01 Issue:2 Volume:6 Page:281
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Locke Frederick L.¹,Go William Y.²,Neelapu Sattva S.³

Affiliation:

1. Department of Blood and Marrow Transplant and Cellular Immunotherapy, H Lee Moffitt Cancer Center & Research Institute, Tampa, Florida

2. Kite, a Gilead Company, Santa Monica, California

3. The University of Texas MD Anderson Cancer Center, Houston, Texas

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

https://jamanetwork.com/journals/jamaoncology/articlepdf/2754748/jamaoncology_locke_2019_rv_190006.pdf

Reference66 articles.

1. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study.;Crump;Blood,2017

2. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.;Cunningham;Lancet,2013

3. Phase III randomized study of R-CHOP versus DA-EPOCH-R and molecular analysis of untreated diffuse large B-cell lymphoma: CALGB/Alliance 50303.;Wilson;Blood,2016

4. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.;Gisselbrecht;J Clin Oncol,2010

5. Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20+ diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma.;Gisselbrecht;J Clin Oncol,2012

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Overview of tumor immunotherapy based on approved drugs;Life Sciences;2024-03

2. Revolutionizing cancer treatment: the power of bi- and tri-specific T-cell engagers in oncolytic virotherapy;Frontiers in Immunology;2024-02-22

3. Plasmablastic lymphoma: current knowledge and future directions;Frontiers in Immunology;2024-02-13

4. Advancing the frontiers of adaptive cell therapy: A transformative mechanistic journey from preclinical to clinical settings;International Immunopharmacology;2023-12

5. Targeted Therapy in Follicular Lymphoma: Towards a Chemotherapy-Free Approach;Cancers;2023-09-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3